Revelation Biosciences, Inc.

REVBW

NASDAQ

Healthcare

Biotechnology

San Diego, CA, US8 employeesrevbiosciences.com

$0.01

+0.00(10.0%)

52W $0.01 – $0.02

AI-generated from 10-K FY2025 filed Feb 25, 2026

Revelation Biosciences, Inc.

$52.1KMkt Cap

—Rev TTM

-$333MNI TTM

-0.8xP/E TTM

Latest Earnings

10-K

FY FY2025Feb 25, 2026

10-K for FY2025 was filed on 2026-02-26. AI summary is not available yet.

Read full analysis View SEC Filing

What Changed Recently

Securities ModificationMar 18, 2026

Material Modification to Rights of Security Holders. Under Nasdaq rules, a listed company may not issue shares at a price below market value in an amount exceed

View filing →

Financial ResultsFeb 25, 2026

and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or ot

View filing →

Material AgreementJan 28, 2026

of this Form 8-K is incorporated herein by reference. The form of the Class J Common Stock Warrants are filed as Exhibit 4.1 to this Form 8-K and is incorporate

View filing →

View all recent events →

Fundamentals

How The Business Makes Money

Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Industry Biotechnology

Company Profile

CIK0001810560

ISINUS76135L1199

CUSIP76135L119

Phone650 800 3717

Address4660 La Jolla Village Drive, San Diego, CA, 92122, US

SEC EDGAR